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BiomarkerMulti-OMICS approaches aim on the integration of quantitative data obtained for different biological molecules
in order to understand their interrelation and the functioning of larger systems. This paper deals with several
data integration and data processing issues that frequently occur within this context. To this end, the data pro-
cessing workﬂow within the PROFILE project is presented, a multi-OMICS project that aims on identiﬁcation of
novel biomarkers and the development of new therapeutic targets for seven important liver diseases. Further-
more, a software called CrossPlatformCommander is sketched, which facilitates several steps of the proposed
workﬂow in a semi-automatic manner. Application of the software is presented for the detection of novel
biomarkers, their ranking and annotation with existing knowledge using the example of corresponding
Transcriptomics and Proteomics data sets obtained frompatients suffering from hepatocellular carcinoma. Addi-
tionally, a linear regression analysis of Transcriptomics vs. Proteomics data is presented and its performance
assessed. It was shown, that for capturing profound relations between Transcriptomics and Proteomics data, a
simple linear regression analysis is not sufﬁcient and implementation and evaluation of alternative statistical ap-
proaches are needed. Additionally, the integration of multivariate variable selection and classiﬁcation approaches
is intended for further development of the software. Although this paper focuses only on the combination of data
obtained from quantitative Proteomics and Transcriptomics experiments, several approaches and data integration
steps are also applicable for other OMICS technologies. Keeping speciﬁc restrictions in mind the suggested
workﬂow (or at least parts of it) may be used as a template for similar projects that make use of different high
throughput techniques. This article is part of a Special Issue entitled: Computational Proteomics in the
Post-Identiﬁcation Era. Guest Editors: Martin Eisenacher and Christian Stephan.
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-NC-ND license.1. Introduction
Multi-OMICS approaches aim on an integration of different biological
entities to understand their interrelation and the functioning of larger
systems [1,2]. Besides their pure gain of knowledge such holistic ap-
proaches also become more and more socially important, because they
may help to solve the problems of an aging population and are key tech-
nologies for personalized and preventive medicine [3,4]. Multi-OMICS
approaches may also be used to identify new biomarkers for (early) dis-
ease diagnostics or they may improve the sensitivity and speciﬁcity of
existing ones [5,6]. Addition of spatial and time aspects enables mathe-
matical modeling (i.e. Systems Biology) [1], which may lead to novel
insights into the mechanisms of pathogenesis and may support the de-
velopment of new therapeutics [7,8].
Systems biologymodels beneﬁt from inclusion of all relevant parts of
the system under consideration [9,10]. On the cellular level, this means
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interaction have to be investigated. Such important bio-molecules com-
prise the genes, which serve as information repository, deﬁning the
constraints of possible cell behavior. Parts of this information (regulated
amongst others by methylation and miRNA) are retrieved by tran-
scription forming mRNA molecules. This enables the production
of proteins, the effector molecules that modulate the cellular state
and behavior. The presence of proteins inﬂuences the amount of
metabolites, i.e. small molecules with various functions (e.g. signaling,
energy transfer and many more).
Therefore, an adequate description of the cell as a system requires the
combination of several molecular biological disciplines that measure
the entirety of bio-molecules: Genomics, Transcriptomics, Proteomics
and Metabolomics. Fortunately, all these so-called “OMICS” approaches
have developed methods that allow quantitative measurements of the
targeted molecules [10,11]. Therefore, main prerequisites are fulﬁlled
in order to give a detailed representation of the dynamics of a cell as a
system. In the long term, these data can be used for development of
mathematical models that may answer questions that cannot be investi-
gated by experimentation alone.
Multi-OMICS approaches entail several issues already concerning
data acquisition: Biological processes may encompass spatial and tem-
poral scales of several orders of magnitude. Though having important
consequences for cellular functioning, the amount of some relevant cel-
lular components can be quite low. In Proteomics for example, absolute
quantitative measurement of such low abundant proteins especially
within complex protein samples, is hampered by technical constraints
or requires application of specialized and often expensive methods.
Furthermore in Proteomics and – less important – in Transcriptomics
usually a mixture of cells in different states has to be analyzed to fulﬁll
“minimum amount” requirements.
Data processing and result interpretation are also demanding due
to different data structures and formats [12], the high amount of data
generated and the need to annotate the experimental ﬁndings with
existing knowledge obtained from the scientiﬁc community.
This paper deals with several data integration and data processing
issues that frequently occur within the context ofmulti-OMICS projects.
To this end, the data processing workﬂowwithin the PROFILE project is
presented, a multi-OMICS project that aims on identiﬁcation of novel
biomarkers and the development of new therapeutic targets for seven
important liver diseases. Although this paper focuses on combination
of data obtained from quantitative Proteomics and Transcriptomics
experiments only, several approaches and data integration steps are
also applicable for other OMICS technologies. Therefore, this workﬂow
(or at least parts of it) may serve as a template for similar projects.
Furthermore, a software called CrossPlatformCommander (abbreviated
as XPlatCom) is sketched, which facilitates several steps of the proposed
workﬂow in a semi-automatic manner.
2. Material and methods
2.1. Data processing within the PROFILE project
Fig. 1 shows a sketch of the multi-OMICS data processing workﬂow
within the PROFILE project. Inputs are both the data generated with
Proteomics and Transcriptomics technologies as well as the patient
and sample characteristics. Output of the workﬂow is high quality bio-
marker candidates ranked with respect to different statistical criteria.
They are also annotated and enriched with existing knowledge and
are structured for easy “manual inspection” by the experimenter.
In the following, the most important steps of the PROFILE workﬂow
are addressed.
2.1.1. Storing patient/sample characteristics and data
Data processing within large projects like PROFILE starts with
collecting and storing different kinds of information obtained byteams that work in different locations (here: surgeons and patholo-
gists in clinics, staff of Transcriptomics and Proteomics measurement
units). In order to ensure a consistent and structured collection of
patient/sample characteristics, database-driven biobanking software
(CentraXX by Kairos GmbH, Bochum, Germany) and a central network-
accessible data repository are mandatory.
Furthermore, high-throughput techniques of multi-OMICS projects
usually yield high amounts of data and therefore strongly beneﬁt from
modern centralized data storage systems: Such systems at least support
handling of large ﬁle sizes. Furthermore, they provide an adequate
fail-safe backup and archiving solution, e.g. a RAID system that is set
up in order to ensure data integrity even in case of hardware failures.
For further information regarding storage solutions for Proteomics facil-
ities please refer to the article “The AminoAcid's Backup Bone— Storage
solutions for Proteomics facilities” in this issue.
2.1.2. Quality Control (QC) and creation of patient/sample groups
Reliable data analysis strongly depends on well characterized
samples and on data that passes the respective technical workﬂow
without major problems. To this end, statistical procedures are used
at the very beginning to assess high quality standards for the experi-
mental data and for building homogenous groups of patients/samples
for inclusion into further comparisons.
We use explorative (e.g. box plots) and multivariate methods
(e.g. hierarchical clustering and principal component analysis)
carried out using the R software environment and the package
arrayQualityMetrics [13] in order to prove the expected global group
structure (e.g. clearly distinguishable groups of healthy and diseased
patients, healthy and abnormal tissue). Details of quality control are be-
yond the scope of this paper because we focus on the comparison and
interpretation of data that pass this QC ﬁlter. Such kind of preliminary
detection and avoidance of technical and biological outliers is indis-
pensable in order to both minimize costs and time efforts and strongly
enhance the reliability of the ﬁndings.
After QC, pseudonymized patient/sample characteristics such as
gender, age, and ethnicity are used for maximizing group homogeneity.
Though R scripts for QC and patient/sample matching are available, the
implementation within XPlatCom is an outstanding task.
2.1.3. Data preparation for ProLiC (XPlatCom module)
2.1.3.1. Data import/conversion. The above mentioned OMICS tech-
niques have been developed within independent scientiﬁc communities
and the technical equipment is developed by different vendors. In sum-
mary, this leads to different ﬁle formats: Currently, patient and sample
characteristics are imported from CentraXX and XPlatCom extracts
protein and peptide identiﬁcation information from ProteinScape 1.3
(Bruker Daltonics, Bremen, Germany), a Proteomics laboratory informa-
tion management system. Furthermore, XPlatCom reads in .csv ﬁles
exported by DeCyder (GE Healthcare, Munich, Germany), a software
for processing 2D DIGE gels and by Progenesis (Nonlinear Dynamics,
Newcastle upon Tyne, UK), a software for LC–MS label-free quantitative
Proteomics. Progenesis result ﬁles contain so-called features. In this
context, a feature denotes a set of isotopes in the “retention time to
m/z”map, which in their entirety originate from a peptide ion. The cor-
responding peptide abundance is calculated by summing up the peak
volumes of this isotope set.
XPlatCom processes Transcriptomics data given in the Affymetrix
CEL data ﬁle format.
2.1.3.2. Internal data structure. To be able to store essentially different
features of transcripts and proteins, XPlatCom internally uses a generic
data structure (using the Java programming language). This structure
consists of different hierarchically organized classes. The Java class bio-
molecule stores feature information shared by transcripts, proteins and
other bio-molecules (e.g. measured expression levels or sequence
Fig. 1. Sketch of the data processing workﬂow performed within the PROFILE project. Transparent parts of the sketch indicate parts, which will be implemented in the near future.
Note, that the “spiral” symbol denotes an iterative application of analysis procedures.
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teristics of the super-class and implement further features (e.g. a set of
protein-related peptides or transcript-related probe sets along with the
quantitation results).
2.1.3.3. Determination of common identiﬁers. Different -OMICS plat-
forms also use different nomenclatures for labeling experimental data,
i.e. different accession numbers or identiﬁers. Enabling their relation is
therefore of high relevance within multi-OMICS projects. Transcript
and protein identiﬁers often have a long-lasting history. Different scien-
tiﬁc communities have assigned different identiﬁers to the same biolog-
ical entity in databases and these identiﬁers may have changed over
time. Therefore, an important data preparation step within PROFILE is
the mapping of protein and probe set identiﬁers to one representative
identiﬁer, the “representative gene name”. For Affymetrix probe sets
the NetAffx Query tool [14] is used to acquire the relationship between
a probe set identiﬁer and a gene name. For protein accessions gene
names are extracted by the Mascot (Matrix Science Ltd., London, UK)
search engine from the UniProtKB/Swiss-Prot database used.
Then, non-primary gene name aliases and synonyms are replaced by
the “representative gene name”. This procedure relies on the informa-
tion given by the gene_info_gz source hosted at the NCBI (ftp://ftp.
ncbi.nlm.nih.gov/gene/DATA/; Entrez Gene [15]). This ﬁle links the
so-called “current ofﬁcial gene symbol”, which origins from a species-speciﬁc nomenclature committee, to a set of known gene name aliases
or previous gene names.
2.1.3.4. Pre-selection. If proteins share the same peptide, its quantiﬁca-
tion is a mix of multiple protein quantiﬁcations. Preliminary data prep-
aration thus also allows determining unique peptides with respect to
the content of a certain protein database. Therefore, the Unique Peptide
Finder software [16] is used to generate a theoretically digested peptide
database from proteins given in the FASTA format. XPlatCom applies
pre-selection in order to eliminate proteins that do not contain a mini-
mum number of peptide identiﬁcations and/or a minimum number of
unique peptides.
It is possible to select only signiﬁcantly regulated Progenesis fea-
tures or probe sets for the calculation of aggregated regulation values.
However, this thresholding procedure is not applied in the analysis
presented in the Results section.
2.1.3.5. Data aggregation. Results from LC–MS label free quantiﬁcation
may comprise different quantiﬁed features belonging to the same
peptide sequence.
Regarding 2D-DIGE experiments, proteinsmay occur in several quan-
tiﬁed gel spots. Furthermore, multiple probe sets of the Affymetrix U219
array plate may have been assigned to the same representative gene
name. XPlatCom calculates aggregated values (possible aggregations:
Table 1
Effect of determining common identiﬁers, pre-selection, and aggregation of peptides/
probe sets on data sets obtained from both Proteomics (LC–MS, DIGE) and
Transcriptomics experiments.
DIGE
Number of proteins 120
Number of proteins after pre-selection 114
Number of peptides after pre-selection 2771
Number of substituted gene name aliases 17
LC–MS (progenesis)
Number of progenesis features with identiﬁcations 22,084
Number of proteins 3293
Number of proteins after pre-selection 2835
Number of peptides (aggregated, after pre-selection) 14,713
Number of substituted gene name aliases 342
Transcriptomics experiment
Number of probe sets 48,801
Number of representative gene names 19,908
Number of substituted gene name aliases 310
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tides, proteins and transcript expressions, respectively.
On demand, XPlatCom can add missing protein sequence informa-
tion from the ExPASy WWW server (http://www.expasy.ch/; [17]), if
Swiss-Prot accessions are available. Therefore, XPlatCom takes advan-
tage of the package ExPASy, which is part of the Biopython project
[18]. For execution of the Python scripts from within Java we use
Jython (version 2.5.2; www.jython.org).
As ﬁnal step of data preparation, the output is stored in a tab
delimited text ﬁle ready for input into the Protein List Comparator soft-
ware (ProLiC, see following section), which handles the next stage of
the PROFILE data processing workﬂow.Fig. 2. A Venn diagram of overlaps and complements of the PROFILE HCC LC–MS, DIGE,
and Transcriptomics bio-molecule groups. Note, that number of bio-molecule groups
obtained for these technology platforms PRINCIPALLY differ: in DIGE only signiﬁcantly
different spots are picked and available for further data processing; in LC–MS not all
proteins are identiﬁed (due to fragmentation undersampling, small dynamic range,
limit of detection). In contrary, Transcriptomics virtually supports measurement of
all mRNA molecules in a sample. Note further, that no thresholding procedure with
respect to p-values of the Student's t-test was applied in this study.2.1.4. Protein List Comparator (ProLiC)
As indicated by the name, the original purpose of ProLiC was
the comparison of protein lists obtained from different Proteomics
experiments. However, the software was extended in order to enable
comparison of Transcriptomics and Proteomics bio-molecules.
ProLiC starts with calculating overlaps and complements for an ar-
bitrary number of protein lists. It can apply three different algorithms,
depending on the information available for a given protein list: acces-
sion numbers, sequences, peptides.
For the ﬁrst algorithm, proteins are identical, if they have equal ac-
cession numbers. However, protein accessions may differ due to differ-
ent databases used for identiﬁcation or due to different versions of
the same database. Therefore, matching of protein identiﬁcations with
respect to accession numbers alone is usually not satisfying.
The second algorithm permits amore reliable comparison of protein
lists from different sources by considering protein sequence informa-
tion. ProLiC supports application of both the Needleman–Wunsch [19]
(global alignment) and the Smith–Waterman [20] (local alignment)
algorithms. “Percent identity” values are calculated for each pairwise
alignment according to the algorithms given by Raghava and Barton
[21]. Two protein sequences are considered as “sufﬁciently identical”
if the calculated percent identity value passes a user deﬁned threshold.
The third algorithm relies directly on peptide sequences that are
identiﬁed by MS experiments. Here proteins pass the identity criteria
if they share the same (or a subset of) peptides. Because the peptide–
spectrum-matches that explain a certain protein are the actual
available information obtained from the Proteomics experiment,
this possibility is considered as the most accurate utilization of the
available information. This technique is applied for the exemplary
analysis in this article.
As the ﬁnal result of ProLiC “sufﬁciently identical” proteins across
all given protein lists are determined (“protein groups”) and thusoverlaps and complements are known and can be visualized in a
Venn diagram.
Currently, ProLiC assigns a transcript to one or more existing
protein groups, if its representative gene name is identical to at
least one protein within this group/these groups. This procedure
leads to a data structure called “bio-molecule group” (BG). A member
of a bio-molecule group is either a transcript or a protein sharing
some characteristics with any other member of the BG. However,
there must be also at least one difference to the other BG group
members; this can be for example the experiment type (e.g. DIGE or
LC–MS) in which the bio-molecule was found. ProLiC saves computed
overlap and complement lists containing bio-molecule groups in a tab
separated ASCII ﬁle format.
2.1.5. Statistics (XPlatCom module)
Overlap or complement lists generated by ProLiC are further
processed to support their inspection and assessment. The statistical
techniques currently implemented have been chosen with respect
to the requirements of the PROFILE project (i.e. biomarker identiﬁca-
tion and drug target discovery).
2.1.5.1. Regression analysis (XPlatCom module). Currently, the presented
workﬂow comprises integration of Transcriptomics and Proteomics
data. In order to evaluate the correlation between both -OMICS ap-
proaches, a linear regression analysis is carried out on both a global
scale (with respect to all calculated transcript and protein regulations
of a list obtained from ProLiC) and on the bio-molecule group level
(considering the protein and transcript regulations of each sample
within a bio-molecule group). Only bio-molecule groups are selected
for regression analysis, where corresponding transcript and protein
regulations exist in more than two samples (otherwise the correlation
coefﬁcient r or the coefﬁcient of determination R2 is 1.0).
As shown previously, neither mRNA nor protein abundances
are normally distributed [22]. Therefore, a transformation procedure
should be applied in order to ensure a correct estimation of signiﬁcance
of the correlation coefﬁcient. We followed Nie et al. [23] and use the
Box–Cox transformation [24] with an automated estimation for the
parameter λ in order to ensure normality distribution. Then, these
Fig. 3. Correlation between the Box–Cox-transformed transcript and protein fold changes (BC–FC) values given for OLDLCT: a) global linear regression analysis and b) distribution of
the coefﬁcient of determination values R2 calculated for each bio-molecule group.
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environment R. The software takes advantage of the R packages car
([25]; CRAN: car) and MASS ([26]; CRAN: MASS).
2.1.5.2. Thresholding and ranking of biomarker candidates (XPlatCom
module). Current high throughput techniques yield huge amounts of
regulated bio-molecule data. Research standards usually require
validation of the ﬁndings using either an independent data set
or/and application of an independent method. Because such validation
procedures are often both expensive and time-consuming a selection
of the most promising biomarker candidates is often mandatory. The
usual way to select bio-molecules is to set thresholds for regulation
(fold change, FC) and p value of a statistical test. In PROFILE, FC de-
notes the regulation of a transcript or a protein between two analysis
groups and p is the result of a paired two — tailed Student's t-test.
Default XPlatCom thresholds are FC > 2 or b0.5 and p b 0.05. Addi-
tionally, XPlatCom ranks the transcripts and proteins of a BG list
using both FC and p. Therefore, the so-called Euclidean distance
deucl is calculated by:
deucl ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
log10 pð Þð Þ2 þ log2 FCð Þð Þ2
q
Logarithms to bases 2 and 10 are intentionally used to equalize the
different scales of FC and p. The higher deucl the larger is the distance
to the origin of the coordinate system. Bio-molecules with the highest
deucl values are the best candidates for subsequent validation.
2.1.6. Integration of existing knowledge from literature and the Kyoto
Encyclopedia of Genes and Genomes (KEGG) database (XPlatCom module)
Integration of existing knowledge is an important task for the in-
terpretation of results. However, both the huge amount of available
information and the diversity of terminologies are challenging:Most bio-
medical information is available in an unstructured format (e.g. articles
in scientiﬁc journals or textual entries in databases). A simple search
within large literature databases that assess information publishedwith-
in the area of life sciences often yields on the one hand many false posi-
tive matches and on the other hand may ignore important information.
In order to cope with these issues, strategies have already been
developed for better retrieval of relevant information using so-called
text mining algorithms. SCAIVIEW (Fraunhofer Institute for Algorithms
and Scientiﬁc Computing SCAI, Sankt Augustin, Germany) is such a soft-
ware for text mining in the biomedical area. SCAIVIEW uses ProMiner
[27] for an advanced terminology and name entity recognition. In the
context of PROFILE several SCAIVIEW queries have been performed
resulting in gene names already associated with speciﬁc disease types.SCAIVIEW result ﬁles also contain “gene name” b-> “KEGG
pathway” relationships. XPlatCom extracts this existing knowledge
into a table, displaying a KEGG pathway identiﬁer together with the
representative gene names from the ProLiC BGs occurring in that
pathway.
2.1.7. Cytoscape
The results of the XPlatComworkﬂow, i.e. bio-molecule groups along
with related information (aggregated expression values, coefﬁcient of
determination values (R2) etc.) can be loaded into the Cytoscape soft-
ware [28–30]. Cytoscape can be used for the production of pathway
visualizations (with colors corresponding e.g. to regression coefﬁcient,
rank, deucl) and for further analysis: For example with the Cytoscape
plug-insMCODE [31] and BinGO [32] it is possible to perform an enrich-
ment analysis and to identify bio-molecules that share the same cellular
function. Further extension of XPlatCom includes a re-import of the
Cytoscape results (as indicated by the “spiral” symbol in Fig. 1) and
annotation of the related bio-molecules with this data. This allows
iterative re-analysis, e.g. a regression analysis of bio-molecules related
to a certain functional category.
2.2. Experimental setup
In the Results section of this article, performance of the software is
demonstrated in the context of hepatocellular carcinoma (HCC), the
ﬁfth most common cancer worldwide [33].
Experimental procedures were carried out in accordance with The
Code of Ethics of the World Medical Association (Declaration of
Helsinki) for experiments involving humans.
Transcriptomics and Proteomics (2D-DIGE and Label free LC–MS)
experiments were carried out with samples obtained from six patients
suffering from hepatocellular carcinoma. Both tumor and normal liver
tissue (from surgicalmargin) sampleswere collected fromeach patient.
2.2.1. Transcriptomics experiments
From human liver needle biopsies (5–8 mg tissue) total RNA was
isolated automatically on a QIAcube using the miRNeasy Micro Kit
according to the protocols of the manufacturer (Qiagen, Hilden,
Germany). Prior to microarray analysis RNA samples were quantiﬁed
on a NanoDrop 1000 (Peqlab, Erlangen, Germany). RNA integrity was
determined on the Experion Automated Electrophoresis System using
the Experion RNA StdSend Analysis Kit (Bio-Rad, Munich, Germany).
After passing those quality controls RNA samples were preprocessed
with the Affymetrix3' IVT Express Kit. Samples were hybridized on
Human Genome U219 16-Array Plates using the AffymetrixGeneTitan
MC Instrument and the GeneTitan Hybridization, Wash, and Stain Kit
(Affymetrix, Santa Clara, CA, USA). The GeneTitan MC Instrument was
Fig. 4. Graphical user interface of the XPlatCom software. The screenshot shows the regression page with the results of regression analyses for the bio-molecule groups of OLDLCT.
The table lists regression results on the BG level (sortable). The diagram shows the Box–Cox transformed values along with the regression line for the BG selected in the table.
Additionally, the results of the global regression analysis are given in the upper right panel.
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(AGCC, version 3.2.4) by which also the CEL ﬁles were processed for fur-
ther downstream analysis. First round GeneChip data quality control
was carried out with the Affymetrix Expression Console Software (ver-
sion 1.2.1).
2.2.2. Proteomics experiments
After protein puriﬁcation (centrifugation at 15000 g for 5 min) a
2D-DIGE minimal labeling experiment was performed. ImageQuant
™ (GE Healthcare, Munich, Germany) is used for image processing.
Relative protein quantitation is carried out with the DeCyder 2D™
software (GE Healthcare, Munich, Germany). Selected differently
expressed protein spots were identiﬁed using MALDI-TOF-MS
(UltraFlex™ II instrument (Bruker Daltonics, Bremen, Germany)) or
nano-HPLC-ESI-MS/MS (Bruker Daltonics HCT plus, Bruker Daltonics,
Bremen, Germany). For LC–MS analysis, 5 μg of each protein sample
was loaded on a 4–20% SDS-PAGE gel (Anamed, Groß-Bieberau,
Germany) and allowed to run into the gel for about 1 cm (15 min
at 50 V). After Coomassie-staining, in-gel trypsin digestion was
performed following standard procedures. Quantitative label-free
analyses were performed on an Ultimate 3000 RSLCnano system
(Dionex, Idstein, Germany) online coupled to a LTQ Orbitrap Velosinstrument (Thermo Scientiﬁc, Bremen, Germany). For each analysis
15 μl of sample was injected, corresponding to an amount of 350 ng
tryptic digested proteins. For the ion-intensity-based label-free quan-
tiﬁcation the Progenesis LC–MS™ software (version 4.0.4265.42984,
Nonlinear Dynamics Ltd., Newcastle upon Tyne, UK) was used. A de-
tailed speciﬁcation of the experimental procedure is given in a subse-
quent paper.2.3. Technical details of the CrossPlatformCommander software
XPlatCom is an application written in the Java programming
language (Java Standard Edition 6, Update 13, Oracle Corporation,
Redwood City, CA, USA). It possesses interfaces for the interaction
with Phyton, Perl (www.perl.org) and for the integration of R scripts
via Rserve 0.6-8 ([34], CRAN: Rserve). The XPlatCom software consists
of several connected modules. Integration of new functionality is
simpliﬁed due to this modular concept. Each module can be used as
a separate command line tool or from within a graphical user inter-
face (GUI, Fig. 4).
The command line tools can be included into user written (shell)
scripts facilitating batch processing of XPlatCom. The results of EACH
Fig. 5. Volcano plot for the proteins in OLDLCT according to FC and Student's t test p-value.
The arrow indicates the proteinwith the largest Euclidean distance value (bold dotted line
to the origin of the coordinate system, i.e. deucl = 5.7). The thin lines mark the applied
thresholds for the fold change (dashed lines correspond to FCs of 2 and 0.5, respectively)
and for the p-value (dotted line corresponds to a p-value of 0.05).
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used as input ﬁles for the subsequent XPlatCom module.
XPlatCom is currently in beta status. A detailed description of the
software and related information (installation, data formats, example
dataset etc.) will be included in the software package at release date
at http://www.medizinisches-proteom-center.de/software.3. Results
Here, performance of the XPlatCom software is demonstrated in the
context of hepatocellular carcinoma (HCC) one of the liver diseases in
focus of the PROFILE project. Due to an ongoing patent registration pro-
cedure neither probe sets, nor protein accessions, nor representative
gene names can be reported. Instead, the principle outcome of some
steps of the data processing workﬂow within the PROFILE project is
presented.3.1. Data preparation for ProLiC
Considering the LC–MS experiment there are in the mean 6.7
features assigned to a protein. After pre-selection and aggregation of
peptides, a protein contains on average 5.2 peptides. In the DIGE
experiment, there is a very high number of peptides (24.3) assigned
on average to each protein.
86% of 3293 (LC–MS) and 95% of 120 (DIGE) of the proteins pass
the protein pre-selection procedure (Table 1).
In the Transcriptomics experiment on average 2.5 probe sets are
aggregated to each representative gene name. For the Proteomics ex-
periments, there is a high proportion of gene names that are consid-
ered as aliases (non-primary gene names) and substituted, i.e. 12%
in LC–MS and 15% in DIGE. For details see Table 1.Table 2
Results of the conducted SCAIVIEW disease queries. The disease queried, the number of rel
SCAIVIEW are given as well. Query number 4 (without MeSH Disease term) is for mapping
Query number Query details
1 [Human Genes/Proteins] AND [MeSH Disease: “Carcinoma, Hepatocellula
2 [Human Genes/Proteins] AND [MeSH Disease: “Liver Diseases”]
3 [Human Genes/Proteins] AND [MeSH Disease: “Neoplasms”]
4 [Human Genes/Proteins]3.2. Application of ProLiC
ProLiC is used to calculate the overlaps and the complements for the
three full-length bio-molecule lists of LC–MS, DIGE and Transcriptomics
experiments (see Fig. 2).
In the remaining sections, the outcome of further data analysis
steps is – except as stated otherwise – shown for the overall DIGE–
LC–MS–Transcriptomics overlap (56 bio-molecule groups). In the
following, this bio-molecule group list is referred as OLDLCT.
3.3. Results of the linear regression analysis
Global correlation calculated for the OLDLCT list is weak (R2 = 0.19,
Fig. 3a). Regarding the overlap of the LC–MS and the Transcriptomics
experiments (1411 bio-molecule groups in Fig. 2) there is almost no
correlation on the global scale (R2 = 0.07; data not shown).
However, within the bio-molecule groups, some of the 56 bio-
molecule groups in OLDLCT show a strong correlation between the
transcript and protein regulations (Fig. 3b). In 11% of the bio-
molecule groups the coefﬁcient of determination is greater than or
equal to 0.8 (for all these coefﬁcients of determination the p-value
of a corresponding F statistics is b0.05). A similar number of well cor-
related bio-molecule groups are found in the overlap of the LC–MS
and the Transcriptomics experiments (8% of the R2 values ≥ 0.8;
data not shown).
3.4. Thresholding and ranking of biomarker candidates
XPlatCom is used to rank bio-molecules of a given BG list. Fig. 5
shows the Volcano plot for proteins in OLDLCT, which are measured by
the LC–MSexperiment. 18 proteins (32%) exhibit FC and p-values better
than the applied thresholds (i.e. FC > 2 or b0.5 and p-value b 0.05).
Most of these proteins are down-regulated between disease vs. healthy
groups.
3.5. Integration of existing knowledge from the literature
On November 7th, 2012 several SCAIVIEW queries regarding HCC
and other diseases were conducted (see Table 2). 41 representative
gene names (73%) of the 56 representative gene names in OLDLCT
have been also found in the SCAIVIEW HCC query. There are no
gene names that were found in the liver disease query, but not for
HCC. 13 representative gene names (23%) have been found in the
neoplasm query, but not in the HCC query (Fig. 6).
3.6. Integration of KEGG pathway information
The SCAIVIEW result ﬁle obtained from the overall gene/protein
query (query number 4 of Table 2) is used to assign the representative
gene names of OLDLCT with KEGG pathways: 59 KEGG pathways are
identiﬁed that contain representative gene names of OLDLCT (some
representative gene names may occur in more than one pathway).
Most of these pathways contain only a small number of bio-molecules
(Fig. 7). However, 18 out of 59 (30.5%) KEGG pathways are related
with 5 or more bio-molecules.ated documents, and the number of representative gene names that were reported by
representative gene names to KEGG identiﬁers.
Disease Number of documents found Number of repr. gene names found
r”] HCC 26,582 4803
Liver disease 6115 1802
Neoplasms 356,893 12,394
– 3,734,116 18,714
Fig. 6. Number of SCAIVIEW hits (representative gene names) found in the results of
HCC, liver disease (LD) and neoplasm queries. Only representative gene names of the
bio-molecule groups in OLDLCT are considered.
Fig. 7. Histogram for the number of gene names in OLDLCT assigned to a KEGG pathway
identiﬁer.
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A workﬂow, which includes several techniques aiming on
integration and processing of data generated in the context of
multi-OMICs projects, was presented. To this end, XPlatCom was
developed, which enables execution of several steps of this workﬂow
in a semi-automated manner. This approach was applied to data of
both Proteomics and Transcriptomics experiments generated within
an ongoing liver disease project (PROFILE).
In this section, the performance of the data processing workﬂow is
discussed in comparison with similar published approaches that refer
on integration of Proteomics and Transcriptomics data. Furthermore,
application of the suggested workﬂow is shown in relation to bio-
marker discovery, a common use case within the PROFILE project.
Possible future extensions of the data processingworkﬂoware sketched
and remaining issues concerning data integration are addressed aswell.
4.1. Performance of the data processing workﬂow
4.1.1. Data integration
Data of both the Proteomics and the Transcriptomics experiments
are linked by representative gene names. Assignment of these com-
mon identiﬁers for both gene and protein entities is considered as a
fundamental step for a combined analysis of multi-OMICs data [1].
Results show that in case of the Transcriptomics data the propor-
tion of substituted aliases is very low (1.6%). However, a relevant part
of the gene names, which are returned by Mascot (extracted from the
used FASTA database) and assigned to proteins of the LC–MS and
DIGE experiments are either gene name aliases or previous names
(12% in the LC–MS and 15% in the DIGE data set). Therefore, the
conversion of these names to the current ofﬁcial gene symbol provid-
ed by the NCBI is considered as crucial data preparation step for en-
suring an optimal data comparison. There are approximately 50% of
the Proteomics BGs that can be matched to transcripts (via represen-
tative gene names). This roughly corresponds to values given in the
literature. Waters et al. cross-reference data obtained from two
mRNA microarray platforms with data obtained from a LC–MS
Proteomics experiment and achieve a 40% overlap [1].
However, the suggested procedure still includes some uncertainty.
NCBI gene names arise from different sources. Amongst others, the
gene_info_gz of NCBI Entrez Gene uses gene names obtained from
species-speciﬁc nomenclature committees. This is in case of human
gene names the HUGO Gene Nomenclature Committee (HGNC), that
currently (2011) provides almost 30,000 approved gene names [35].Nevertheless, the “current ofﬁcial gene symbols” are not unique
between species. Therefore, it is intended to extend the XPlatCom
software with a mapping opportunity to NCBI GeneIDs, because
these identiﬁers are unique across all taxa.4.1.2. Regression analysis
A major feature of the suggested data processing workﬂow is the
calculation of correlation between transcripts and proteins. Globally,
only 19% of the variance in the protein regulations of the OLDLCT list
can be explained by the transcript regulations. However, a weak
global correlation between the protein and the messenger RNA
expression ratio has frequently been reported [23,36]. Waters et al.
review several quantitative studies comparing mRNA and protein
abundance and report very low correlation in particular for studies
that consider mammals [1]. Lower eukaryotes, like for example yeast,
usually show a closer coupling of gene and protein regulations. Waters
attributes this to a stronger relationship between genes that control cell
cycle and metabolism in lower eukaryotes.
The results of our study are in general agreement with several
similar mammalian studies. It has been estimated that differential
expression of mRNA can determine the corresponding protein expres-
sions by only 20%–40% [10,37,38]. Chen et al. [39] compare gene and
protein expressions of 76 lung adenocarcinomas and 9 control samples
(86 samples in total). Global correlation for this data set gives a
Spearman correlation coefﬁcient of−0.025. Another study uses a set of
60 human cancer cell lines and performs a comparative study with pro-
tein and mRNA expression patterns. On the mRNA level both cDNA
microarrays and Affymetrix oligonucleotide chips are utilized. Global re-
gression analysis over all 60 cell lines yields coefﬁcient of correlation
values of 0.27 (cDNA vs. protein) and 0.16 (oligonucleotide vs. protein),
respectively. Tian et al. compared kinetic changes of both mRNA and
protein levels for mouse (Mus musculus) liver samples depending on
drug response [38]. R2 obtained from global regression analysis is 0.29.
Several reasons may account for the low agreement of regulation
on the Transcriptomics and Proteomics level. In has been frequently
suggested that post-transcriptional regulatory mechanisms are very
important [1,40]. Waters et al. [1] estimate that these mechanisms
account to more than ﬁfty percent to the discordance between mRNA
and protein abundance proﬁles.
Regarding the mRNA this includes export from the nucleus and
splicing of pre-mRNA. The life cycle of mRNA is strongly regulated and
the half-lives-of mRNA individuals may vary by several orders of mag-
nitude [41]. Furthermore, mechanisms that control translation contrib-
ute largely to the variation of mRNA-protein correlations [42,43].
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highly speciﬁc and regulatedmechanisms including for example protein
folding and ubiquitin-mediated protein degradation [44]. Considering
the complex interrelationship between gene and protein expression
levels, occurrence of rather low coefﬁcient of determination values is
not surprising.
As a result, the correlation between Transcriptomics and Proteomics
data is most likely far from linearity. Additionally, protein data is
often biased towards high abundant proteins [23]. Therefore, capturing
existing correlations within such data sets strongly depends on the
ability of the statistical methods applied to cope with these issues and
incorporating of adequate methods is a crucial task for a comparison
of Transcriptomics and Proteomics experiments. Such techniques com-
prise data transformation and normalization, compensating incomplete
proteomic data and statistical methods that are sensitive for non-linear
relationships (for review, see [10,23]).
4.1.2.1. Data transformation and normalization. XPlatCom currently
includes Box–Cox transformation in order to ensure normality.
However, normalization with respect to the length of both tran-
scripts and proteins was suggested for the improvement of correla-
tion [23]. Implementation of this technique is currently under
development.
4.1.2.2. Handling of incomplete proteomic data and the detection of non-
linear correlations. Several methods have been suggested for estimation
of missing values in a given Proteomics dataset with respect to the avail-
ablemeasurements. This includes for example a ‘knearest neighbor algo-
rithm’, the ‘row-mean method’, which was applied to a neuroblastoma
DIGE dataset [45,46] and a ‘zero inﬂated Poisson regression model’,
which was adapted for the prediction of missing protein abundance
values [47]. In order to cope with the non-linear correlation between
Transcriptomics and Proteomics data, a ‘stochastic gradient boosted
trees’ approach can be used that outperforms the results of simple linear
regression analysis [48].
Improvement of the regression module is considered a major task
of further development. To this end, the performance of several of the
above mentioned techniques will be evaluated with respect to the
HCC data set.
4.1.2.3. Context related regression analysis. Another important aspect
regarding the correlation of Proteomics and Transcriptomics data is
considering the context of pathways and biological functioning [49,50].
It has been frequently observed that correlation of Proteomics and
Transcriptomics data is related to subcellular localization and functional
categories [40,50–52]. For example, it has been shown that correlations
related to the localization categories ‘Nucleus’ and ‘Cell periphery’ are
signiﬁcantly higher than the global correlation [40]. Beyer et al. [50]
observed strong correlation between mRNA and protein abundance for
the functional categories ‘metabolism’, ‘energy’, and ‘protein synthesis’.
Furthermore, molecular machines (e.g. the ribosome, [53]) and protein/
gene pairs with structural functioning [54] show a high mRNA–protein
correlation.
4.2. Choice of biomarker candidates
Discovery of novel biomarkers is a complex task. There are several
important characteristics that should be considered while selecting
new biomarker candidates. For some important characteristics, rele-
vant information is provided by the XPlatCom software and selection
of promising biomarker candidates is strongly facilitated.
First, promising biomarker candidates show signiﬁcant regulations
with respect to the conditions under consideration. Additionally, differ-
entially expressed bio-molecules should pass the t-test criteria. To this
end, the ranking according to calculated deucl values, which takes both
measures into account, is suitable for selection of such biomarkercandidates. However, volcano plots reveal the contribution of each
measure to the deucl value. This enables selection of biomarker candi-
dates with preference of either fold change or p-value.
Second, accounting for known relations, which are obtained from
the literature, is also important. Findings that agree with the results
that have been reported for the considered disease conﬁrm the
reliability of the experimental setup. However, the most important
ﬁndings are new discoveries, which are promising novel biomarker
candidates. SCAIVIEW result ﬁles can be utilized for both purposes.
Optionally, gene names are indicated that have been related with
several disease categories of interest. In case of the HCC study, liver
diseases or neoplasms is selected as ‘co-related’ categories. The most
promising candidates are most likely these bio-molecules that are
reported in neither SCAIVIEW result list, because they have not
been associated with the hepatocellular carcinoma, other liver dis-
eases or another neoplasm before.
Third, multivariate variable selection and classiﬁcation are an
important means for the development of assays suitable of disease rec-
ognition. Bio-molecules are interacting withmany other bio-molecules.
There aremany factors that inﬂuence the expression level of a transcript
or a protein. Because diseases usually alter the functioning of at least
the affected cells or even the ‘steady state’ of the individual as a
whole, measurement of a single biological entity is most likely not suf-
ﬁcient to clearly detect a disease or to differentiate between disease
stages. Therefore, considering a panel of transcript and protein expres-
sion measurements will most likely improve both the speciﬁcity and
sensitivity of a biomarker.
Therefore, it is intended to include several multivariate variable se-
lection and classiﬁcation procedures into the PROFILE data processing
workﬂow. Implementation of these techniques as amodule of XPlatCom
is an on-going process. For example, an R package named PAA is devel-
oped at our institute (http://www.medizinisches-proteom-center.de/
software) for Protein microarray analysis (using a random forest classi-
ﬁer approach [55]). This R package includes a multivariate wrapper
method along with a backwards elimination algorithm that iterates
through different feature (e.g. protein) subsets. Then, the classiﬁer is
applied to a current subset. PAA will be adopted for multi-OMICS data
analysis.4.3. Further extension of the data processing workﬂow
Further development of the XPlatCom software concerns integration
of further OMICS platforms (miRNA, DNAmethylation and SNP experi-
ments). Signiﬁcantly different miRNA expressions could be related
to signiﬁcant down-regulations of the mRNA belonging to the gene
repressed by that miRNA, if known. Otherwise, data may be utilized
to hypothesize, which gene is repressed by a miRNA, if that is still
unknown. A similar analysis may be performed to show, whether a
methylation pattern corresponds to inactivation of neighboring genes.
Concerning measurement of both protein and gene expression
levels, the data collection scheme of the PROFILE project includes
only DIGE/Label free and DNA microarray technologies.
However, there are different approaches available for both OMICS
platforms. Regarding quantitative Proteomics a large methodological
branch introduces differential mass tags into the protein or peptide
that do not alter their biochemical characteristics. Such techniques are
frequently grouped into ‘metabolic labeling’ (e.g. SILAC) and ‘chemical
labeling’ (e.g. ITRAQ, ICPL, ICAT etc.) strategies (for review see [56–58]).
In comparison with label free both metabolic and chemical labeling
approaches show a higher precision. Additionally, labeling enables the
absolute quantitation of protein changes even within complex protein
samples (AQUA method, [59]).
On the other hand, label freemethods are inexpensive. Furthermore,
these techniques require no additional steps for data acquisition and
they can be applied to data sets obtained from standard LC–MS/MS
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method ﬁts all” opportunity in the ﬁeld of quantitative Proteomics.
On the contrary, in Transcriptomics a new developed technique
named RNA sequencing (RNA-seq) has drawn great attention
[60,61]. There are considerable advances in comparison with the
well-established hybridization-based microarray techniques, e.g. a
higher dynamic range, low background noise, a low amount of nec-
essary RNA for measurement, etc. [61]. Therefore, this technology
may substitute DNA microarrays as standard for gene expression
proﬁling studies.
Basically, the XPlatCom software is a generic tool for the processing
of quantitative Proteomics and Transcriptomics data. Therefore, each
of the above mentioned techniques is supported.
However, the data output formats providedby different vendors and
different scientiﬁc communities strongly vary and the programming of
converters is a necessity for importing data from e.g. ITRAQ or RNA-seq
experiments into XPlatCom. A huge diversity of data formats is a com-
mon task in bioinformatics. In both Proteomics and Transcriptomics
the relevance of this issue has been recognized. Several initiatives
have been founded that aim on the developing of standard formats.
Amongst others, the Proteomics Standards Initiative (PSI) develops
MzQuantML [62], which is a standard format that handles results
obtained from quantitative experiments that measure proteins and
peptides by mass spectrometry. The format supports both label free
and labeling techniques. Final release of MzQuantML is announced for
early 2013 (Gerhard Mayer, editor of the PSI Proteomics Informatics
group, personal communication).
Amongst other things, the Functional Genomics Data Society
(FGED, [63]) aims on development of standard data formats and
required minimum information standards for Transcriptomics exper-
iments. FGED provides two standard formats for microarray data
(MAGE-ML [64] and MAGE-TAB [65]). To the best of our knowledge
there is no standard format available for RNA-seq data.
In summary, standardization strongly facilitates sharing of data
and the usage of available software tools. In order to provide analysis
of data obtained from a broad range of Transcriptomics and Proteomics
techniques, further development of the XPlatCom software includes
consideration of available standard data formats.
5. Conclusions
A workﬂow for processing and integrating multi-OMICS data was
presented using the example of corresponding Transcriptomics and Pro-
teomics data sets obtained from patients suffering from hepatocellular
carcinoma. The software CrossPlatformCommander (XPlatCom), which
facilitates the execution of several tasks of such a workﬂow, was also
presented. Application of the software was shown for the detection of
novel biomarkers, their ranking and annotationwith existing knowledge.
However, for capturing correlations between Transcriptomics and
Proteomics data, a simple linear regression analysis is not sufﬁcient. In
the future, a search for bio-molecule sub-groups (e.g. built with respect
to similar molecular function or cellular localization) with potentially
better correlations may reveal meaningful trends in co-analyzed
Transcriptomics and Proteomics data. Implementation and evaluation
of alternative statistical approaches, which are adapted to cope with
the non-linearity of such relationships, are also promising. Additionally,
another important task is the integration of the multivariate variable
selection and classiﬁcation approach.
Keeping speciﬁc restrictions in mind the suggested workﬂow may
be used as a template for similar projects even when considering
different high throughput techniques.
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